Mack Roach

About

Dr. Mack Roach is a leading authority in the treatment of prostate cancer, with a career dedicated to refining radiotherapy techniques to improve patient outcomes. His research primarily focuses on stereotactic body radiotherapy (SBRT), brachytherapy, and the comparative effectiveness of radical therapies. Dr. Roach’s most cited work, a 2012 study with 459 citations, provides a critical comparative analysis of prostate-specific antigen (PSA) free survival across risk groups, establishing a benchmark for evaluating treatment success. He has pioneered adaptive stereotactic robotic brachytherapy, demonstrating an innovative workflow that integrates MR-stealth robots for precise, real-time treatment delivery. His investigations into interfraction anatomical variability have shown how daily changes can significantly increase rectal dose during SBRT, leading to more robust planning protocols. Dr. Roach also advanced plan quality and consistency by standardizing dose constraints for CyberKnife treatments. His notable achievements include developing new management options for localized prostate cancer that prioritize quality of life. With a career spanning over two decades, Dr. Roach’s work has profoundly shaped modern prostate cancer radiotherapy, making him a pivotal figure in the field.

Research Focus

Key Achievements

Top Papers

1. 1
   Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

   459 citations · 2012
2. 2
   Toward adaptive stereotactic robotic brachytherapy for prostate cancer: Demonstration of an adaptive workflow incorporating inverse planning and an MR stealth robot

   32 citations · 2010
3. 3
   Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer

   30 citations · 2016
4. 4
   Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife

   21 citations · 2013
5. 5
   New techniques and management options for localized prostate cancer.

   8 citations · 2006
6. 6
   Outcomes of Hypofractionated SBRT Boost for Intermediate- and High-Risk Prostate Cancer: A Single Institutional Prospective Study

   2 citations · 2013

Key Collaborators

Contact & Links